Emergent BioSolutions Inc (EBS)
4.345
-0.02
(-0.57%)
USD |
NYSE |
May 10, 16:00
4.345
0.00 (0.00%)
After-Hours: 19:02
Emergent BioSolutions Enterprise Value: 1.056B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 1.056B |
| May 08, 2024 | 1.058B |
| May 07, 2024 | 1.058B |
| May 06, 2024 | 1.036B |
| May 03, 2024 | 1.031B |
| May 02, 2024 | 1.000B |
| May 01, 2024 | 928.54M |
| April 30, 2024 | 925.92M |
| April 29, 2024 | 926.44M |
| April 26, 2024 | 928.01M |
| April 25, 2024 | 929.58M |
| April 24, 2024 | 941.63M |
| April 23, 2024 | 947.40M |
| April 22, 2024 | 940.58M |
| April 19, 2024 | 934.30M |
| April 18, 2024 | 924.86M |
| April 17, 2024 | 926.96M |
| April 16, 2024 | 929.58M |
| April 15, 2024 | 931.15M |
| April 12, 2024 | 935.34M |
| April 11, 2024 | 942.16M |
| April 10, 2024 | 944.25M |
| April 09, 2024 | 948.44M |
| April 08, 2024 | 948.97M |
| April 05, 2024 | 947.40M |
| Date | Value |
|---|---|
| April 04, 2024 | 946.35M |
| April 03, 2024 | 945.82M |
| April 02, 2024 | 940.58M |
| April 01, 2024 | 947.92M |
| March 31, 2024 | 959.97M |
| March 28, 2024 | 881.05M |
| March 27, 2024 | 884.19M |
| March 26, 2024 | 876.33M |
| March 25, 2024 | 881.10M |
| March 22, 2024 | 874.31M |
| March 21, 2024 | 877.44M |
| March 20, 2024 | 879.53M |
| March 19, 2024 | 876.92M |
| March 18, 2024 | 877.44M |
| March 15, 2024 | 876.40M |
| March 14, 2024 | 871.18M |
| March 13, 2024 | 865.44M |
| March 12, 2024 | 870.13M |
| March 11, 2024 | 894.67M |
| March 08, 2024 | 888.93M |
| March 07, 2024 | 893.10M |
| March 06, 2024 | 918.68M |
| March 05, 2024 | 926.51M |
| March 04, 2024 | 913.98M |
| March 01, 2024 | 925.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
826.80M
Minimum
Feb 07 2024
7.660B
Maximum
Aug 13 2020
2.900B
Average
2.828B
Median
Enterprise Value Benchmarks
| Avid Bioservices Inc | 627.44M |
| Viking Therapeutics Inc | 7.882B |
| FibroGen Inc | 56.95M |
| Avinger Inc | 15.58M |
| RAPT Therapeutics Inc | 2.947M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 9.00M |
| Revenue (Quarterly) | 292.40M |
| Total Expenses (Quarterly) | 252.60M |
| EPS Diluted (Quarterly) | 0.17 |
| Gross Profit Margin (Quarterly) | 50.55% |
| Profit Margin (Quarterly) | 3.08% |
| Earnings Yield | -251.8% |
| Normalized Earnings Yield | -72.37 |